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LDL-C reduction of $17.12. In comparison, the costs 
per percent LDL-C reduction for equipotent strengths of
other statins were ﬂuvastatin 80mg at $17.93, simvas-
tatin 20mg at $36.84, pravastatin 40mg at $37.66 and
lovastatin 40mg at $47.29. Acquisition costs per unit for
these agents were $1.78, $1.72, $3.53, $3.51 and $4.02,
respectively. CONCLUSION: Acquisition cost is one
component in evaluating cost of therapy. However, in this
analysis, among equipotent agents, the agent with the
lowest acquisition cost was not the most cost effective.
Attempts to quantify cost effectiveness should be made
when reviewing the statin class.
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OBJECTIVES: Estimate the cost-effectiveness ratio in
France of treating high vascular risk patients with sim-
vastatin. METHODS: Data on efﬁcacy and resources
consumed were extracted from the published results of
the MRC/BHF Heart Protection Study (HPS) performed
in UK. HPS compared the occurrence of total and CHD
deaths, major vascular events (MVE), and major coro-
nary events (MCE) in more than 20,000 patients with
high vascular risk (patients with diabetes, history of
stroke or other cerebrovascular disease, peripheral arter-
ial disease, or with CHD). Patients were randomly
assigned to receive simvastatin or placebo and followed
at least for ﬁve years. The cost-effectiveness analysis was
performed using French unit costs. The survival beneﬁt
over the study period was estimated from the HPS results.
Direct costs included the extra costs of simvastatin and
the beneﬁt associated with avoided vascular events. Indi-
rect costs were not considered. Costs and beneﬁt were
discounted at 5%. RESULTS: All-cause mortality was
reduced by 13% (RR = 0.87, p = 0.0003). There was a
discounted survival beneﬁt of 0.040 year per included
patient. There were highly signiﬁcant reductions of about
one quarter in the risk of ﬁrst event rate of MVE (RR =
0.76, p < 0.0001) and of MCE (RR = 0.73, p = 0.0001).
The absolute value of the percentage of avoided event
during the 5-year period in the simvastatin group was
5.4% for any major vascular event, 2,1% for non fatal
MI, 1.3% for non fatal stroke, 2.4 % for revascularisa-
tion, 1.2% for fatal MI and 0.2% for fatal stroke. The
discounted extra cost of simvastatin was estimated at
€1994 ($1 = €1) taking into account the statins used in
the placebo group. This cost was reduced to €1031 by
considering the direct cost associated with avoided vas-
cular events. Cost-effectiveness ratio was then estimated
at €23,678 per life year gained (€22,000 to €50,000 
in the different subcategories of patients, ratios well
accepted as being cost-effective). CONCLUSIONS: Treat-
ment with simvastatin in different subcategories of
patients with high vascular risk is cost-effective in the
French setting.
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OBJECTIVES: Studies examining costs following
myocardial infarction (MI) have been limited by short
follow-up, small sample sizes, restricted patient popula-
tions, or failure to include hospital, physician, or market
characteristics. In a national sample with extensive sup-
plemental data, we sought to identify the baseline factors
predicting higher costs in the year following MI.
METHODS: Elderly acute MI patients totaling 84,373
(90% white, 49% female) in the Cooperative Cardiovas-
cular Project were linked to Medicare Part A claims, AHA
Hospital Surveys, the CMS directory of physician spe-
cialties, and the CMS Hospital Wage Index File. Medicare
charges were converted to costs using institutional cost to
charge ratios. Associations with admission episode and
one-year log-transformed costs were assessed by regres-
sion analysis with robust standard errors. RESULTS:
Mean cost was $12,956 (median $8,833) for the admis-
sion episode and $19,597 (median $13,583) at one year.
Patient characteristics accounted for 11% of the admis-
sion and one-year cost variation. Patient variables most
highly associated with one-year costs included anterior
MI, CHF, COPD, renal insufﬁciency, diabetes, and shock.
Older age (age 80 years) was most strongly associated
with lower costs. After adding hospital, physician, and
market variables, the models explained 22% of admission
and 17% of the one-year cost variation. Teaching hospi-
tals and care by a cardiologist were both associated with
higher one-year costs. While patient death was associated
with lower admission episode costs, death after the initial
episode was associated with higher one-year costs. CON-
CLUSION: In models examining the baseline predictors
of one-year costs following MI, patient characteristics
account for approximately twice the cost variation
accounted for by other baseline variables.
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